Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 10/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | DGKA | P23743 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30108992 | 0.92 | ALDH1A1 (0.34) | PRKCADGKAL3MBTL1MEN1KMT2A | |
| SCHEMBL30108857 | 0.85 | PRKCA (0.36) | PRKCANAAATSHRTDP1L3MBTL1 | |
| SCHEMBL30108872 | 0.76 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL10895062 | 0.71 | PRKCA (0.43) | PRKCANAAAMEN1KMT2AEPHX2 | |
| SCHEMBL30114903 | 0.70 | KMT2A (0.39) | TSHRTDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL30114958 | 0.70 | KMT2A (0.39) | TSHRTDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL30064001 | 0.69 | CNR2 (0.37) | PRKCANAAATSHRTDP1L3MBTL1 | |
| SCHEMBL28186350 | 0.68 | NAAA (0.43) | PRKCANAAADGKATSHRL3MBTL1 | |
| SCHEMBL8810368 | 0.67 | ALDH1A1 (0.45) | NAAATSHRTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL7536987 | 0.64 | CYP2C19 (0.47) | PRKCANAAADGKATSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4101833-B1 | PROCESSES FOR PREPARING A (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETATE COMPOUND AND (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETALDEHYDE | SHINETSU CHEMICAL CO (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-11731930-B2 | Processes for preparing a (1,2-dimethyl-3-methylenecyclopentyl)acetate compound and (1,2-dimethyl-3-methylenecyclopentyl)acetaldehyde | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20230002305-A1 | PROCESSES FOR PREPARING A (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETATE COMPOUND AND (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETALDEHYDE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-01-05 | — | — | US | disclosed |
| EP-4101833-A1 | PROCESSES FOR PREPARING A (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETATE COMPOUND AND (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETALDEHYDE | Shin-Etsu Chemical Co., Ltd. (JP) | 2022-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731930-B2 | Processes for preparing a (1,2-dimethyl-3-methylenecyclopentyl)acetate compound and (1,2-dimethyl-3-methylenecyclopentyl)acetaldehyde | ADH1C, AKR1C4, AKR1C2 | PRKCA 1640/4885NAAA 1781/4885DGKA 611/4885 |
| US-20230002305-A1 | PROCESSES FOR PREPARING A (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETATE COMPOUND AND (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETALDEHYDE | ADH1C, AKR1C4, AKR1C2 | PRKCA 1640/4885NAAA 1781/4885DGKA 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.